Immunosuppression is an independent prognostic factor associated with aggressive tumor behavior in cutaneous melanoma - 17/08/15
Abstract |
Background |
A number of factors other than those identified by the American Joint Committee on Cancer (AJCC) may have prognostic significance in the evaluation of melanoma.
Objective |
We sought to evaluate commonly recorded clinical features potentially associated with aggressive melanoma.
Methods |
We conducted a retrospective case-control study. We included patients given a diagnosis of cutaneous melanoma with at least 5 years of follow-up or documented metastases. Patients were divided into nonaggressive and aggressive groups. Univariate and multivariate statistical analyses were performed to evaluate the association of multiple clinical and histologic parameters and metastases.
Results |
We included 141 patients. Significant prognostic factors in univariate analysis associated with nonaggressive disease included history of dysplastic nevus syndrome and ABCDE criteria. Significant factors in univariate analysis associated with aggressive disease included age and immunosuppression. Only age and immunosuppression remained significant in multivariate analysis when controlled across statistically significant histologic variables from AJCC.
Limitations |
The study is retrospective and has a small sample size.
Conclusion |
Older patients and those with a history of immunosuppression may be at higher risk for aggressive disease and should be closely monitored after an initial diagnosis of melanoma.
Le texte complet de cet article est disponible en PDF.Key words : ABCDE criteria, age, dysplastic nevus syndrome, immunosuppression, melanoma, metastatic melanoma
Plan
| Dr Donahue and Ms Lee contributed equally to this article. |
|
| Supported by the Irene D. Pritzker Foundation. |
|
| Disclosure: Dr Gerami served as a consultant, receiving honoraria, for Castle Biosciences Inc, DermTech Inc, and Myriad Genetics. Dr Ferris served as a consultant and principal investigator, receiving honoraria, for Castle Biosciences Inc and DermTech Inc. Drs Donahue, Sidiropoulos, and Yelamos, Ms Lee, Ms Sanghvi, Ms Obregon, Ms Cooper, and Ms Merkel have no conflicts of interest to declare. |
Vol 73 - N° 3
P. 461-466 - septembre 2015 Retour au numéro
Article précédent
- Combined cutaneous tumors with a melanoma component: A clinical, histologic, and molecular study
- Sapna M. Amin, Chelsea Cooper, Oriol Yélamos, Christina Y. Lee, Lauren M. Sholl, Arnaud de la Fouchardiere, Joan Guitart, Pedram Gerami
- Early-onset childhood vitiligo is associated with a more extensive and progressive course
- Euphemia W. Mu, Brandon E. Cohen, Seth J. Orlow
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?